• About
  • Tests
  • Solutions
    • Firefighters
  • Resources
  • News
  • Contact
  • Download Test Order Form
Order Tests Now
Exploring Early Cancer Detection with the EPISEEK™ Liquid Biopsy: Insights from Dr. Joshua Routh on the Beautifully Broken Podcast

Exploring Early Cancer Detection with the EPISEEK™ Liquid Biopsy: Insights from Dr. Joshua Routh on the Beautifully Broken Podcast

by Amy Cook | Jul 1, 2025 | News

Watch the full episode on Youtube In the world of health and wellness, the phrase “early detection” is incredibly powerful, especially when it comes to cancer. We know that diagnosing cancer at an earlier stage generally leads to better outcomes. While...
Dr. Richard Bernert and Dr. Dan Rubin discuss Catching Cancer Early: A Game Changer with EPISEEK™

Dr. Richard Bernert and Dr. Dan Rubin discuss Catching Cancer Early: A Game Changer with EPISEEK™

by Amy Cook | Jul 1, 2025 | News

Watch the full episode on Youtube. Dr. Dan Rubin, host of Rubin on Point! hosted our very own Dr. Richard Bernert, COO of Precision Epigenomics! With a background as a pathologist – essentially the expert who helps clinicians understand disease at the cellular level –...
Precision Epigenomics Presents Validation of EPISEEK™, a Multi-Cancer Early Detection Test, at 2025 ASCO Annual Meeting

Precision Epigenomics Presents Validation of EPISEEK™, a Multi-Cancer Early Detection Test, at 2025 ASCO Annual Meeting

by pesbm | Jun 24, 2025 | News

The data support the EPISEEK™ test’s potential as an accurate and cost-effective solution for multi-cancer early detection through a simple blood draw. PHOENIX, AZ, UNITED STATES – June 2, 2025 /EINPresswire.com/ — Precision Epigenomics, a biotechnology...
Precision Epigenomics Highlighted by Tucson News 13 for Multi-Cancer Early Detection Blood Test Development

Precision Epigenomics Highlighted by Tucson News 13 for Multi-Cancer Early Detection Blood Test Development

by pesbm | Feb 21, 2025 | News

Tucson’s News 13 recently highlighted Precision Epigenomic’s groundbreaking work developing EPISEEK™, a multi-cancer early detection blood test. The segment focused on EPISEEK that looks for signals shared by more than 50 types of cancer through a simple blood draw,...
Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection 

Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection 

by pesbm | Jan 13, 2025 | News

Precision Epigenomics announced that the company presented data supporting the critical role of its melanoma classifier. TUCSON, Az. - Nov. 21, 2024 - /EINPresswire.com/ — Precision Epigenomics, the developer of the EPISEEK™ multi-cancer detection (MCD) test,...
Precision Epigenomics Announces Closing of $1.5M Series A1 Funding 

Precision Epigenomics Announces Closing of $1.5M Series A1 Funding 

by pesbm | Sep 10, 2024 | News

With this funding, Precision Epigenomics has raised more than $3.9M in investments helping move the company into the revenue stage. TUCSON, Az. - Sept. 10, 2024 - Precision Epigenomics Inc. announces the completion of a $1.5M Series A1 preferred stock round of funding...
« Older Entries

Recent Posts

  • Exploring Early Cancer Detection with the EPISEEK™ Liquid Biopsy: Insights from Dr. Joshua Routh on the Beautifully Broken Podcast
  • Dr. Richard Bernert and Dr. Dan Rubin discuss Catching Cancer Early: A Game Changer with EPISEEK™
  • Precision Epigenomics Presents Validation of EPISEEK™, a Multi-Cancer Early Detection Test, at 2025 ASCO Annual Meeting
  • Precision Epigenomics Highlighted by Tucson News 13 for Multi-Cancer Early Detection Blood Test Development
  • Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection 

Recent Comments

No comments to show.
The EPISEEK™ test is recommended for use in adults with an elevated risk for cancer, such as those aged 45 or older. The EPISEEK™ test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK™ is intended to detect cancer signals. Use of EPISEEK™ is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected does not completely rule out cancer. A test result of Abnormal Methylation Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm or exclude the presence of cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK™ false positive) or confirmatory testing was insufficient to detect a very early cancer (follow up testing false negative). False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Quick Links

Home
About
Tests
Resources
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522



520.777.7367

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow